Elite Pharma Inc (ELTP)

Currency in USD
0.4467
+0.0705(+18.74%)
Closed·
ELTP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.37610.4467
52 wk Range
0.27000.8194
Key Statistics
Prev. Close
0.3762
Open
0.38
Day's Range
0.3761-0.4467
52 wk Range
0.27-0.8194
Volume
1.21M
Average Volume (3m)
744.26K
1-Year Change
-13.8975%
Book Value / Share
0.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELTP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Elite Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Elite Pharma Inc Company Profile

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Employees
68

Elite Pharma Inc Earnings Call Summary for Q2/2026

  • Elite Pharmaceuticals reported Q2 FY2026 revenue of $36.3M, up 92% YoY, with operating profits rising 136% to $8.2M despite a 13.11% stock price decline following earnings release.
  • Operating cash flow surged 333% YoY to $19.9M, while working capital increased 63% to $75M from March 2025, demonstrating strong operational efficiency.
  • The company projects annual revenue to exceed $100M, driven by successful product launches including a generic version of Vyvanse and strategic M&A initiatives.
  • CEO Nasrat Hakim identified M&A as 'primary focus,' with the company actively exploring acquisition opportunities and potential international expansion into the Israeli market.
  • Elite confirmed an anticoagulant ANDA filing for Q1 2026 and full DEA quota allocations, though faces challenges from patent litigation for generic OxyContin and increasing market competition.
Last Updated: 11/18/2025, 01:54 AM
Read Full Transcript

Compare ELTP to Peers and Sector

Metrics to compare
ELTP
Peers
Sector
Relationship
P/E Ratio
34.5x−4.5x−0.5x
PEG Ratio
0.130.110.00
Price/Book
7.8x5.1x2.6x
Price / LTM Sales
3.9x2.6x3.3x
Upside (Analyst Target)
-63.9%45.7%
Fair Value Upside
Unlock15.2%6.5%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
36.32M / --
EPS Revisions
Last 90 days

ELTP Income Statement

People Also Watch

82.53
CALM
-2.08%
87.83
LRN
+1.62%
371.08
IDCC
+7.54%
7.690
CRMD
+4.63%
271.63
RMD
+1.72%

FAQ

What Is the Elite Pharma Inc (ELTP) Stock Price Today?

The Elite Pharma Inc stock price today is 0.4467

What Stock Exchange Does Elite Pharma Inc Trade On?

Elite Pharma Inc is listed and trades on the OTC Markets.

What Is the Stock Symbol for Elite Pharma Inc?

The stock symbol for Elite Pharma Inc is "ELTP."

What Is the Elite Pharma Inc Market Cap?

As of today, Elite Pharma Inc market cap is 481.05M.

What Is Elite Pharma Inc's Earnings Per Share (TTM)?

The Elite Pharma Inc EPS (TTM) is 0.01.

From a Technical Analysis Perspective, Is ELTP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Elite Pharma Inc Stock Split?

Elite Pharma Inc has split 2 times.

How Many Employees Does Elite Pharma Inc Have?

Elite Pharma Inc has 68 employees.

What is the current trading status of Elite Pharma Inc (ELTP)?

As of Feb 07, 2026, Elite Pharma Inc (ELTP) is trading at a price of 0.4467, with a previous close of 0.3762. The stock has fluctuated within a day range of 0.3761 to 0.4467, while its 52-week range spans from 0.2700 to 0.8194.

What Is the ELTP After Hours Price?

ELTP's last after hours stock price is 0.4651, the stock has decreased by -0.0036, or -0.7700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.